SEC Form 4 · accession 0001628280-26-059904

Crinetics Pharmaceuticals, Inc. · CRNX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Weston Nichols

Director

Period of report

Sep 1, 2026

Accepted (ET)

Sep 1, 2026 · 5:01 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001658247

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Sep 1, 2026	D	16,300	$85.00	D	5,925	D
Common Stock^F2	Sep 1, 2026	D	5,925	$85.00	D	0	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Stock Option (Right to Buy)^F3,F4	$23.24	Sep 1, 2026	D	12,500	D	—	Jun 21, 2029	Common Stock	12,500	D
Stock Option (Right to Buy)^F3,F4	$23.23	Sep 1, 2026	D	12,500	D	—	Jun 19, 2030	Common Stock	12,500	D
Stock Option (Right to Buy)^F3,F4	$20.23	Sep 1, 2026	D	17,500	D	—	Jun 22, 2031	Common Stock	17,500	D
Stock Option (Right to Buy)^F3,F4	$18.29	Sep 1, 2026	D	17,500	D	—	Jun 17, 2032	Common Stock	17,500	D
Stock Option (Right to Buy)^F3,F4	$20.32	Sep 1, 2026	D	17,500	D	—	Jun 15, 2033	Common Stock	17,500	D
Stock Option (Right to Buy)^F3,F4	$44.71	Sep 1, 2026	D	12,500	D	—	Jun 7, 2034	Common Stock	12,500	D
Stock Option (Right to Buy)^F3,F4	$32.33	Sep 1, 2026	D	10,350	D	—	Jun 11, 2035	Common Stock	10,350	D
Stock Option (Right to Buy)^F3,F4	$35.87	Sep 1, 2026	D	9,730	D	—	Jun 18, 2036	Common Stock	9,730	D

Explanation of responses

F1Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").
F2The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding.
F3The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.
F4The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.